Rehabilitation Training and Resveratrol Improve the Recovery of Neurological and Motor Function in Rats after Cerebral Ischemic Injury through the Sirt1 Signaling Pathway.

This study was conducted to investigate the recovery of motor function in rats through the silent information regulator factor 2-related enzyme 1 (Sirt1) signal pathway-mediated rehabilitation training. Middle cerebral artery occlusion (MACO) was used to induce ischemia/reperfusion injury. The rats were subjected to no treatment (model), rehabilitation training (for 21 days), resveratrol (5 mg/kg for 21 days), and rehabilitation training plus resveratrol treatment. 24 h later, They were assessed for neurobehavioral score and motor behavior score and expression of brain derived-nerve neurotrophic factor (BDNF) and tyrosine kinase receptor B (TrkB). Compared with sham group, models had significantly higher neurobehavioral scores, balance beam, and rotary stick scores. Compared with the model group, rats in rehabilitation training and resveratrol groups had significantly reduced scores. Compared with rehabilitation training or resveratrol treatment alone, rehabilitation plus resveratrol further reduced the scores significantly. The percentage of cells expressing BDNF and TrkB and expression levels of BDNF and TrkB were similar between the model and sham groups, significantly increased in rehabilitation training and resveratrol groups, and further increased in rehabilitation training plus resveratrol group. These results indicate that rehabilitation raining plus resveratrol can significantly improve the recovery of motor function in rats after cerebral ischemic injury, which is likely related to the upregulation of the BDNF/TrkB signaling pathway.

1. Introduction

Cerebrovascular disease is a major hazard to human health and life. Ischemia resulting from middle cerebral artery occlusion (MCAO) accounts for nearly 80% of cerebrovascular diseases, which have higher incidence, disability, and mortality rate and are heavy burden to the patient's family and society [1-3]. At present, the clinical treatments of ischemic cerebral vascular diseases is mainly relied on early thrombolysis, nerve protection and rehabilitation. Among them, rehabilitation training is most widely used, which helps to improve the patient's body movement, feeling, language, and cognition ability. Studies have shown that rehabilitation training can increase cerebral blood flow, promote the survival of neurons after cerebral infarction, inhibit cerebral swelling, and stimulate the secretion of neuron growth factors and neurotrophic factors to improve or restore nerve and limb movement ability [4-7]. However, in most of the previous studies, drug treatment or rehabilitation training alone is used to improve the neurological and motor function. Fewer studies have dealt with combined therapy of drug and rehabilitation.

Silent information regulator factor 2-related enzyme 1 (Sirt1) is a member of the sirtuins family. It is an acetylated protein closely related to the age and aging. Studies have shown that Sirt1 is not only associated with inflammation, osteoarthritis, diabetes, cardiovascular disease, and cancer, but also associated with the progression of neurodegenerative diseases [8-10]. A large number of studies have shown that Sirt1 or its agonist resveratrol has a significant protective effect on neurons in rats after middle cerebral artery occlusion (MCAO) [11-15]. In addition, antioxidant transcription factor Nrf2 is also activated by resveratrol to upregulate the target genes such as NAD(P)H:quinone oxidoreductase 1, γ-glutamylcysteine synthetase, and heme oxygenase-1 to protect endothelial cells [16]. However, other mechanisms underlying resveratrol mediated protection, particularly when used in combination with physical therapy, need to be further explored.

In this study, we investigate the effect of combined therapy of rehabilitation training plus resveratrol on the recovery of neural function, motor function in MCAO rats, and possible mechanisms underlying the effect. The findings would provide insights into additional role of resveratrol and rehabilitation for better clinical therapeutic use.

2. Materials and Methods

2.1. Animals

Two-month-old male SD rats (SPD grade), weighting 200 ± 20 g, were purchased from Silaike Experimental Animal Co., Ltd., Shanghai (certificate number 2012-0002) and were hosted in animal rooms at 23 ± 2°C with free access to food and drinking water.

2.2. Reagents and Instruments

Resveratrol was purchased from Sigma (lot number 34092-100 mg), USA; BCA protein assay kit, mouse anti-GAPDH monoclonal antibody, and horseradish peroxidase-labeled goat anti-rabbit IgG (H plus L) were purchased from Beytime Biotechnology (lots numbers P0010, AG019, and A0208), Beijing; rabbit anti-BDNF and TrkB polyclonal antibodies were purchased from Abcam (lots numbers ab108319 and ab18987), USA; Trizol kit and One-Step RT-PCR kit were purchased from Invitrogen (lots numbers 15596-018 and AM1005), USA. Electrophoresis apparatus, transfer apparatus, and gel imaging system were purchased from Bio-Rad, USA; plate reader was from TECAN, Swiss, and fluorescence microscope AF6000 was obtained from Leica, Germany. All animal experimental protocols were approved by the research ethic committee of Linyi Chinese Medicine Hospital.

2.3. Modeling

MCAO models were constructed as previously described [4, 5]. Briefly, the rats were anaesthetized using 10% chloric aldehyde. The right common carotid artery (CCA), right internal carotid artery (ICA), and right external carotid artery (ECA) were separated, ECA and ICA were ligated, and ICA was clipped. A small incision was made on ECA near CCA and inserted slowly with a nylon line to a depth of about 18 mm to generate MCAO. After 2 h of ischemia, the nylon line was slightly withdraw to allow reperfusion for 22 h. For sham group, ECA, CCA, and ICA were separated but not ligated.

2.4. Grouping and Drug Treatments

Rats were equally grouped into sham (n = 24), model (n = 24), rehabilitation training (n = 24), resveratrol (n = 24), and rehabilitation plus resveratrol groups (n = 24). Rehabilitation training started 24 h after the operation as described ([4, 5]), including crawling on balance beams and rotary bars rotating alternatively clockwise and counterclockwise at 3 rpm. The training lasted 10 min twice daily for 21 days. Resveratrol was given by daily abdominal injection with 5 mg/kg resveratrol for 21 days [17].

2.5. Neurological Behavior and Motor Function Assessment

Twenty-four hours after the surgery, the rats were assessed for neurological function based on the Longa Zea scoring method [4, 5]. Rats scored 1 to 3 were randomized for subsequent experiments. They were assessed again at 2, 7, 14, and 21 days after surgery before rehabilitation training and resveratrol administration. The rats were also assessed for motor function before rehabilitation training and resveratrol administration as previously described [6].

2.6. Tissue Sampling

21 days after the surgery, rats were sacrificed and the brain tissues were isolated and washed in prechilled saline. Cortex tissues taken from middle cerebral artery area were fixed in 10% neutral formalin for immunohistochemical assay or stored at −80°C for Western blot and RT-PCR analyses.

2.7. Immunohistochemical Assay

Fixed cortex tissues were imbedded in paraffin and sectioned and immersed in 3% hydrogen peroxide for 15 min to remove endogenous peroxidase. After being blocked with nonimmune animal serum and washed with PBS, the slides were incubated in primary antibody solutions at room temperature for 2 h, washed with PBS, and incubated with horseradish peroxidase-labeled goat anti rabbit IgG (H+L) at 37°C. The slides were developed in DAB solution and counterstained with hematoxylin. Dark brown or yellow-browed colored cells were considered positive, and the positive percentages were calculated using Image J software based on average light density.

2.8. RT-PCR

BDNF and TrkB mRNA expression was analyzed by RT-qPCR on total RNA isolated from cortex tissues using the Trizol reagent according to the supplier's protocols. Reverse transcription was performed with 200 ng of RNA in a total volume of 10 μL using One-Step RT-PCR kit according to manufacturer's recommendations. The amplified products were separated on 2% agarose gel by electrophoresis. RT-qPCR was performed on the 7900HT Fast Real-Time PCR system using TaqMan gene expression assays probes (Applied Biosystems). The primers used for BDNF were 5′-TATCCTTATGAACCGCCAGCC (forward) and 5′-TTCTGACATTAAGGGCCGTG (reverse) and for TrkB were 5′-CAAGTTGGCGAGACATTCCA (forward) and 5′-AGTCATCGTCGTTGCTGATGAC (reverse). Human glyceraldehyde-3-phosphate dehydrogenase, GADPH (Hs03929097_g1), was amplified using a pair of primers 5′-AGCCACATCGCTCAGACA (forward) and 5′-TGGACTCCACGACGTACT (reverse) as an internal control. The PCR was carried out in a total volume of 10 μL containing 1.5 μL of diluted and preamplified cDNA, 10 μL of TaqMan Gene Expression Master Mix, and 1 μL of each fluorescence TaqMan probe. The cycling conditions were 50°C for 2 min, 95°C for 10 min followed by 40 cycles, each one consisting of 45 s at 95°C and 45 s at 59°C with final extension at 72°C for 60 s. Samples were run in triplicate and the mean value was calculated for each case.

The data were managed using the Applied Biosystems software RQ Manager v1.2.1. Relative expression was calculated by using comparative Ct method and obtaining the fold change value (2−ΔΔCt) according to previously described protocol [18].

2.9. Western Blot

To detect BDNF and TrkB protein expression, total proteins were extracted from the brain tissue in RIPA lysis buffer. The protein concentration was determined using the BCA kit. Sixty μg of the proteins was separated by SDS-PAGE and transferred (Bio-Rad, USA) to PVDF membranes (Millipore, USA). BDNF and TrkB protein expression levels were quantified using rabbit polyclonal antibodies specific for each protein. The expression levels of these proteins were standardized to human GADPH using a mouse polyclonal anti-GADPH antibody. Primary antibodies were detected using goat anti-rabbit or goat anti-mouse horseradish peroxidase- (HRP-) conjugated secondary antibodies. Immunoreactive bands were visualized using Western Lighting Chemiluminescence Reagent Plus (PerkinElmer, USA) according to the manufacturer's instructions and then quantified by densitometry using a Bio-Rad gel imaging system and Quantity One software.

2.10. Statistical Analysis

All data were expressed as means ± standard error of the mean (SEM) obtained from at least three independent experiments and analyzed using the statistical software SPSS 17. Means were compared using one-way ANOVA or repeated measures ANOVA. Tukey's test was used as the post hoc test to determine mean differences within groups. A P value ≤ 0.05 was considered statistically significant.

3. Results

3.1. Neurobehavioral Assessment

As shown in Table 1, the neurobehavioral scores were significantly higher in the model group than in the sham groups 7 days after operation (P < 0.01), while the rats in rehabilitation training and resveratrol groups had significantly lower scores as compared to those in the model group (P < 0.01). Furthermore, the scores were further lowered in rehabilitation training plus resveratrol group (P < 0.01). These score decreases were statistically significant within 7 days of treatment and more remarkable as the time increased after the surgery (Table 1). In most cases, there were significantly effects of time on the outcome of neurobehavioral scores except for sham (Table 1). ANOVA analyses showed that rehabilitation training, resveratrol, rehabilitation training plus resveratrol, and therapy time had significantly impact on improvement of neurobehavioral scores (F = 5.37, 4.22, 4.03, and 9.12, resp., P < 0.01).

Table 1

Neurobehavioral scores of rats following middle cerebral artery occlusion/reperfusion injury, rehabilitation training, and resveratrol treatment.

Groups	Days after the surgery
	2	7	14	21
Sham	0A	0A	0A	0A
Model	2.38 ± 0.24∗∗,A	1.79 ± 0.18∗∗,B	1.37 ± 0.13∗∗,B	1.00 ± 0.10∗∗,C
Rehabilitation training	2.01 ± 0.15∗∗,A	0.88 ± 0.09∗∗,##,B	0.59 ± 0.05∗∗,##,C	0.28 ± 0.03##,D
Resveratrol	2.00 ± 0.12∗∗,A	0.87∗∗, ± 0.08∗∗,##,B	0.60 ± 0.06∗∗,##,C	0.29 ± 0.03##,D
Rehabilitation training plus resveratrol	1.96 ± 0.17∗∗,##,A	0.56∗∗, ± 0.05##,++,B	0.40 ± 0.04##,++,C	0.12 ± 0.01##,++,D

∗∗, ##, and  ++ denote values with P < 0.01 versus sham, model, and rehabilitation training or resveratrol, respectively. Numbers labelled with different capital letters in the same row are significantly different (P < 0.01) based on repeated measures ANOVA.

3.2. Kinematic Behavior Assessment

We then assessed the kinematics behavior scores of the rats and the results are shown in Tables 2 and 3. Seven days after operation, balance beam and rotary stick scores were significantly (P < 0.01) higher in the model groups than in the sham group and significantly (P < 0.01) lower in rehabilitation training group and resveratrol group than in model group. The scores were further reduced significantly (P < 0.01) in rehabilitation plus resveratrol group). These scores began to decrease significantly after 7 days of treatment throughout entire experimental period (Tables 2 and 3). In most cases, there were significant effects of time on the outcome of balance beam scores and rotary stick scores except for sham (Tables 2 and 3). In ANOVA analysis rehabilitation training, resveratrol, rehabilitation training plus resveratrol, and therapy time had shown significant variation in balance beam scores (F = 5.57, 6.22, 3.03, and 7.12, resp., P < 0.01) and rotary stick scores (F = 4.37,5.22,7.03, and 5.12, resp., P < 0.01).

Table 2

Balance beam scores of rats following middle cerebral artery occlusion/reperfusion injury, rehabilitation training, and resveratrol treatment.

Groups	Days after the surgery
	2	7	14	21
Sham	1.00 ± 0.00A	1.00 ± 0.00A	1.00 ± 0.00A	1.00 ± 0.00A
Model	5.08 ± 0.52∗∗,A	2.79 ± 0.28∗∗,B	2.24 ± 0.3∗∗,B	1.69 ± 0.17∗∗,C
Rehabilitation training	5.01 ± 0.50∗∗,A	1.83 ± 0.19∗∗,##,B	1.48 ± 0.15∗∗,##,C	1.19 ± 0.12∗∗,##,D
Resveratrol	5.00 ± 0.52∗∗,A	1.85 ± 0.18∗∗,##,B	1.49 ± 0.15∗∗,##,B	1.20 ± 0.12∗∗,##,C
Rehabilitation training plus resveratrol	4.98 ± 0.17∗∗,A	1.45 ± 0.15∗∗,##,++,B	1.23 ± 0.12∗∗,##,++,C	1.06 ± 0.10##,++,D

  ∗∗, ##, and ++ denote values with P < 0.01 versus sham, model, and rehabilitation training or resveratrol, respectively. Numbers labelled with different capital letters in the same row are significantly different (P < 0.01) based on repeated measures ANOVA.

Table 3

Rotary stick scores of rats following middle cerebral artery occlusion/reperfusion injury, rehabilitation training, and resveratrol treatment.

Groups	Days after the surgery
	2	7	14	21
Sham	0A	0A	0A	0A
Model	2.28 ± 0.22∗∗,A	1.95 ± 0.19∗∗,B	1.46 ± 0.13∗∗,C	1.12 ± 0.11∗∗,D
Rehabilitation training	2.21 ± 0.20∗∗,A	1.42 ± 0.13∗∗,##,A	1.07 ± 0.11∗∗,##,C	0.53 ± 0.05∗∗,##,D
Resveratrol	2.20 ± 0.22∗∗,A	1.43 ± 0.14∗∗,##,B	1.05 ± 0.10∗∗,##,C	0.53 ± 0.05∗∗,##,D
Rehabilitation training plus resveratrol	2.17 ± 0.21∗∗,A	1.10 ± 0.10∗∗,##,++,B	0.90 ± 0.09∗∗,##,++,B	0.36 ± 0.04∗∗,##,++,C

  ∗∗, ##, and  ++ denote values with P < 0.01 versus sham, model, and rehabilitation training or resveratrol, respectively. Numbers labelled with different capital letters in the same row are significantly different (P < 0.01) based on repeated measures ANOVA.

3.3. Expression of BDNF and TrkB

To analysis changes at the molecular level, we assessed the expression of BDNF and TrkB in the brain tissues 21 days after the operation and the results are shown in Table 4 and Figures 1 –4. In comparison with sham group, the positive percentages, protein, and mRNA levels for the two genes did not change in the model group (P > 0.05). However, these parameters were significantly (P < 0.01) increased in rehabilitation training or resveratrol groups and were further increased significantly (P < 0.01) in rehabilitation training plus resveratrol group.

Table 4

Positive percentages of BDNF and TrkB in brain tissue of following middle cerebral artery occlusion/reperfusion injury, rehabilitation training, and resveratrol treatment.

Groups	Positive percentage of BDNF	Positive percentage of TrkB
Sham	28.17 ± 2.82	18.90 ± 1.89
Model	29.86 ± 2.99	20.17 ± 0.21
Rehabilitation training	42.35 ± 4.40##	38.47 ± 3.85##
Resveratrol	42.29 ± 4.23##	38.49 ± 3.85##
Rehabilitation training plus resveratrol	68.56 ± 6.26##,++	56.19 ± 5.62##,++

## and  ++ denote values with P < 0.01 versus sham, model, and rehabilitation training or resveratrol, respectively.

Figure 1

Immunohistochemistry staining of brain cells for BDNF (×400). (a) Sham operation group; (b) model group; (c) rehabilitation training group; (d) resveratrol group; (e) rehabilitation training plus resveratrol group.

Figure 2

Immunohistochemistry staining of brain cells for TrkB (×400). (a) Sham operation group; (b) model group; (c) rehabilitation training group; (d) resveratrol group; (e) rehabilitation training plus resveratrol group.

Figure 3

BDNF and TrkB protein expression in brain tissues 21 days after the operation. (a) Representative Western blot; (b) relative protein content. ## and ++ denote values with P < 0.01 versus sham, model, and rehabilitation training or resveratrol, respectively.

Figure 4

PCR analysis of BDNF and TrkB mRNA expression in brain tissues. (a) Electrophoresis of PCR product; (b) relative mRNA levels. ## and ++ denote values with P < 0.01 versus sham, model, and rehabilitation training or resveratrol, respectively.

4. Discussion

Ischemic cerebrovascular disease or ischemic stroke is one of the major causes of disability in the elderly. The incidence of the disease is increasing rapidly as the population ages and recovery of motor functions after ischemic stroke has attracted increasingly attentions [1-3]. While rehabilitation training has been shown to be effective for improving the conditions of stroke patients for motor function and cognitive ability [4-7], the molecular mechanisms are still poorly understood.

As a member of silence information regulator 2 (Sir2) family, Sirt1 is a nicotinamide adenine dinucleotide- (NAD+-) dependent histone deacetylase. It regulates the transcription of a number of downstream genes through NAD+ to participate in various cellular processes such as apoptosis, cell cycle, cell energy metabolism, oxidative stress, and cell aging process and is involved in a number of diseases such as diabetes, tumor, inflammation, aging, and neural degenerative diseases [8-10]. Earlier studies have revealed that the upregulation of Sirt1 activity or use of Sirt1 agonist resveratrol attenuates neurological injury in rats after cerebral ischemia through increased antioxidant capacity and neuronal survival although the mechanisms are largely unknown [11-15]. Also, it is not clear if rehabilitation training and Sirt1 agonist resveratrol have synergy in the recovery of motor functions after cerebral ischemia.

Our study shows that, from 7 to 21 days after operation, the recovery of motor functions in MACO rats was significant in a time-dependent manner as indicated by decreased neurobehavioral scores, balance beam, and rotary stick scores after rehabilitation training or resveratrol treatment. These results are consistent with early works [6, 19]. Furthermore, these scores were further reduced in rats receiving rehabilitation training plus resveratrol, suggesting that there is synergy between rehabilitation training and resveratrol.

Research shows that the recovery of damaged nerve after cerebral ischemia may be promoted through the secretion of various neurotrophic factors, which bind to their receptors to activate downstream signaling systems [20, 21]. BDNF is a neurotrophic factor widely distributed in endocrine cells, bone tissues, the central nervous system, and the peripheral nervous system. It is shown to promote neuronal growth, survival, and injury repair and plays significant role in neurogenesis and neurodegenerative diseases [20, 21]. BDNF has two kinds of receptors. One is low affinity receptor p75, capable of binding with all the neurotrophic factor families, and the other is Trk, including TrkA, TrkB, and TrkC. TrkB is known to be the strongest receptor of BDNF and is mostly studied. BDNF binds TrkB to form ligand-receptor complex to activate tyrosine kinase and then downstream signaling pathways such as phosphatidylinositol 3 kinase (PI3K), extracellular regulating kinase (ERK), and mitogen-activated protein kinase (MAPK) signaling pathway to regulate synaptic function and synthesis of neuronal proteins and restore neuronal regeneration and survival [22, 23]. Research has shown that in cerebral ischemic rats BDNF/TrkB expression is upregulated to stabilize ischemia-induced Ca2+ imbalance, inhibit the toxic effect of excitatory amino acids on neurons, and stimulate the survival and regeneration of damaged neurons as well as differentiation and proliferation of neural stem cells [24-26]. Rehabilitation training has been found to increase the expression of BDNF in cerebral ischemia mice [27] and in the serum of patients with Parkinson's disease [28]. On the other hand, resveratrol is shown to increase the expression of Sirt1 as well as BDNF and its receptor TrkB [29] in elderly rats, suggesting that Sirt1 might protect retinal neurons and visual function through the regulation of BDNF/TrkB. Sirt1 is also shown to have neuroprotective effect in patients with Huntington's disease, and the effect is associated with the upregulation of BDNF/TrkB signaling pathway [30]. These results imply that the recovery of neural function and motor function in rats with cerebral ischemia may be related to the BDNF/TrkB signaling pathway. To elucidate the molecular mechanisms of the functional recovery, we analyzed the expression of BDNF and Trk in the brain tissues. Our study shows that 21 days after surgery, there was no difference in BDNF/TrkB expression at protein and mRNA levels between the sham and model groups, which is similar to the early study [31]. However, between 3 and 14 days after operation, the model group had higher but gradually decreasing BDNF/TrkB expression as compared to the rats in sham group. This might be due to the secretion of endogenous neurotrophic factors in early cerebral ischemia stage that restores the nerve and motor functions, while in late cerebral ischemia stage, the self-recovery is decreased, resulting in a decrease in expression of BDNF and TrkB. On the other side, the expression of BDNF and TrkB was significantly increased after rehabilitation training and resveratrol treatment, suggesting that both therapies may upregulate the BDNF/TrkB signaling pathway, resulting in the recovery of nervous system function and motor function in the cerebral ischemic rats. Resveratrol has been shown to activate antioxidant transcription factor Nrf2 to confer endothelial protection via upregulation of target genes that reduce the oxidative stress [16], a protective mechanism different from the one observed in our study. Furthermore, further increase in BDNF and TrkB expression in the combined rehabilitation training and resveratrol treatment as compared to single treatment was observed, indicating that there is synergistic effect on the neurological function and motor function recovery between rehabilitation training and resveratrol treatment.

In conclusion, rehabilitation training and resveratrol can individually and synergistically improve the recovery of neurological function and motor function in rats after cerebral ischemic injury and this therapeutic effect is likely achieved through the upregulation of the BDNF/TrkB signaling pathway.